Prader-Willi Syndrome (PWS) Market

Prader-Willi Syndrome (PWS) Market - Snapshot

Prader–Willi syndrome (PWS) is a genetic disorder caused by a loss of function of specific genes on chromosome 15. In newborns, symptoms include weak muscles, poor feeding, and slow development. Beginning in childhood, those affected become constantly hungry, which often leads to obesity and type 2 diabetes. Mild to moderate intellectual impairment and behavioral problems are also typical of the disorder. Often, affected individuals have a narrow forehead, small hands and feet, short height, light skin and hair. Most are unable to have children. About 74% of cases occur when part of the father's chromosome 15 is deleted. In another 25% of cases, the affected person has two copies of the maternal chromosome 15 from the mother and lacks the paternal copy. As parts of the chromosome from the mother are turned off through imprinting, they end up with no working copies of certain genes. PWS is not generally inherited, but rather the genetic changes happen during the formation of the egg, sperm, or in early development. No risk factors are known for the disorder. Those who have one child with PWS have less than a 1% chance of the next child being affected. A similar mechanism occurs in Angelman syndrome, except the defective chromosome 15 is from the mother, or two copies are from the father.

Prader–Willi syndrome has no cure. Treatment may improve outcomes, especially if carried out early. In newborns, feeding difficulties may be supported with feeding tubes. Strict food supervision is typically required, starting around the age of three, in combination with an exercise program. Growth hormone therapy also improves outcomes. Counseling and medications may help with some behavioral problems. Group homes are often necessary in adulthood.

Prader Willi syndrome (PWS) is a complex genetic disorder results from the lack of expression of genes on the paternally-inherited genes in the15q11.2-q13 chromosome region. The burden of multisystemic complex genetic disorder in patients has been increasingly characterized by massive bearings it has on metabolic, endocrine, and neurologic systems, marred by hypothalamic dysfunction. The patients characteristically suffer from severe hypotonia, particularly neonatal hypotonia, with troubling implications in behavior and intellectual difficulties continuing to later years of life. The condition has led to stunted development. A key drive for PWS market comes from the its prevalence in global populations—estimated as 1/10,000–1/30,000—which is significant irrespective of race, gender, and ethnicities. The key causative factor for the high morbidity and mortality in PWS is obesity.

In developed and developing nations, the rise in uptake in DNA methylation testing has propelled the evolution of the PWS market. In emerging economies, molecular testing with DNA methylation has gained ground in hospital settings. A growing understanding of the etiology and pathophysiology is key to boosting the growth prospects in the market. Policymakers around the world are intent on raising awareness about the burden of the disease to promote early diagnosis and early treatment. These might lead to overall better outcomes, and will offer new opportunities for healthcare players to implement behavioral and cognitive strategies.   

Prader-Wili syndrome (PWS) is a rare genetic disorder, which causes problems in intellectual development, behavior, physical growth, mood, and eating. This rare genetic disorder occurs due to changes in chromosome 15, which is responsible for regulating the gene expression. Difficulty to control eating is a major symptom among people with PWS. Other symptoms include moderate to high learning disabilities, possess a compulsive behavior, outbursts, and stubbornness.

Newborns with this disorder may have small hands and feet, almond shaped eyes, and a triangular mouth.  Other factors that define PWS included reduced development of genital organs, feeding difficulties, quick weight gain, uncontrollable overeating, and extremely weak muscles. The disorder also causes incomplete or delayed puberty among individuals of both sexes; therefore, they are unable to have children.

In many of the cases, the Prader-Wili syndrome is inherited. However, in some cases the anomaly can take place which can be caused due to malfunctioning of chromosome 15. This may be passed from one generation to the next, especially in maternal uniparental disomy and deletion in paternal chromosome 15. Genetic changes may occur randomly during the formation of reproductive cells or during early development of embryo. In such cases, affected people may or may not have a history of the disorder in their family.

Prader-Willi Syndrome (PWS) Market – Competitive Landscape

Chong Kun Dang Pharmaceutical Corp

Founded in 1941, Chong Kun Dang is headquartered in Seoul, South Korea. Company is leading pharmaceutical & biotechnological company in Korea. Company offers range of prescription drugs for anti-diabetics, anticancer, anti-hypertension, health supplements, prebiotics and healthy beverage products. Few of the drugs for Prader-Willi Syndrome (PWS) treatment are under pipeline.  Chong Kun Dang Pharmaceutical Corp is the first Korean pharmaceutical company which has got U.S. FDA approval and which export some of the products to the U.S. market.

LG Life Sciences Ltd.

Founded in 2002, LG Life Sciences Ltd. is headquartered in Seoul, South Korea. The company specializes in specialty chemicals in South Korea and international market. Company also offers range of products in animal health products as well as pharmaceuticals. In pharmaceutical segment company offers treatment products for Prader-Wili syndrome, fertility treatment related products, hormones, viscosupplements used during the treatment of degenerative diseases, chemical vaccines etc.

Prader-Willi Syndrome (PWS) Market – Dynamics

Growth hormone continues to be the major constituent of overall therapeutic contribution:-

Currently, pharmacological drugs and therapy for Prader-Willi Syndrome are concentrated primarily on the usage of human growth hormone (HGH) supplementation, which is permitted in the U.S. Supplementation of growth hormone continues is one of the major constituent of overall therapeutic contribution of the market due to nearly pervasive deficiency of growth hormone (GH) in patients suffering from PWS syndrome.  Accepted growth hormone therapies in North America and Europe include Genotropin by Pfizer, Nordotropin by Novo Nordisk, and Ominitrope (somatropin injection) from Sandoz. Growth hormone therapies which are increasingly used to treat PWS patients, especially older patients are central nervous system and cardiovascular agents.

Clinical Trials Pave the Way for PWS Treatments:-

Increase in investment to find innovative solution for the Prader-Willi syndrome (PWS) by pharmaceutical and biotech companies is expected to drive the market. Many clinical trials are taking place around the world which are helping to better understand syndrome and to develop novice products/ therapy for the treatment of PWS. However, side effects and high cost of these therapies are likely to hinder the global Prader-Willi syndrome market. 

Prader-Willi Syndrome (PWS) Market – Segmentation

The Prader-Willi Syndrome (PWS) market can be divided into:

• Product Type
• Application
• Region

Prader-Willi Syndrome (PWS) Market Segmentation – By Product Type

Depending on the product type, the Prader-Willi Syndrome (PWS) market can be divided into:

• Betahistine Hydrochloride
• FE-992097
• Beloranib
• Diazoxide Choline CR
• NOX-B11

Prader-Willi Syndrome (PWS) Market Segmentation – By Application

Depending on the Application, the Prader-Willi Syndrome (PWS) market can be divided into:

• Hospitals
• Clinics
• Others